T reg DLI (Mario Arpinati)

N/A

Report date: 2022/11/19 14:24:01

Base Information

Drug NameT reg DLI (Mario Arpinati)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsGraft vs Host Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAzienda Ospedaliera-Universitaria Di Bologna Policlinico S. Orsola-Malpighi

China Registration ClassN/A

Develop Information

Active CompaniesAzienda Ospedaliera-Universitaria Di Bologna Policlinico S. Orsola-Malpighi

Inactive CompaniesN/A

Active IndicationsGraft vs Host Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A